Related Experiment Videos
Treatment of Androgen-Independent Prostate Cancer
1Beth Israel Hospital and Harvard Medical School, Division of Hematology/Oncology, Boston, Massachusetts, 02215, USA.
Abstract:
Androgen-ablative therapy for metastatic prostate cancer is effective for 60%-80% of men, but its effects are always finite and the majority of men develop androgen-independent disease within two years. Although current therapies for androgen-independent disease have not been shown to impact on survival, recent clinical and laboratory insights offer hope for effective therapy. For instance, recent data indicate that androgen-independent disease may still be dependent on hormonal stimulation, suggesting that hormonally based therapies may provide continued benefit. Chemotherapy, especially with estramustine and etoposide, seems to be an effective combination for a majority of patients. Treatment with suramin had been hampered by its side effects, but new dosing schedules are effectively circumventing toxicity. Radioisotopes such as strontium 89 have been shown to provide effective palliation for a majority of androgen-independent patients. Overall, these and other emerging efforts may be the foundation for therapies that offer hope for a significant survival benefit.
Insights
Androgen-ablative therapy for prostate cancer eventually fails, leading to androgen-independent disease. Emerging treatments like chemotherapy and novel hormonal therapies offer new hope for improved survival.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Androgen-ablative therapy (AAT) is a primary treatment for metastatic prostate cancer, effective in 60%-80% of patients.
- Disease progression to androgen-independent prostate cancer (AIPC) is common within two years, limiting AAT efficacy.
- Current AIPC therapies have not demonstrated significant survival benefits.
Purpose of the Study:
- To review recent clinical and laboratory insights into AIPC treatment.
- To highlight emerging therapeutic strategies for AIPC.
- To explore potential for improved survival in advanced prostate cancer.
Main Methods:
- Review of recent clinical data and laboratory findings on AIPC.
- Analysis of emerging treatment modalities including chemotherapy, hormonal therapy, and radioisotopes.
- Evaluation of novel dosing schedules for existing drugs.
Main Results:
- AIPC may remain hormone-dependent, suggesting continued benefit from hormonal therapies.
- Combination chemotherapy (estramustine, etoposide) shows efficacy in a majority of patients.
- Suramin toxicity is being managed with new dosing schedules; strontium 89 offers palliation.
Conclusions:
- Emerging therapies offer hope for managing AIPC.
- Novel approaches may provide significant survival benefits for patients with advanced prostate cancer.
- Continued research into AIPC is crucial for developing more effective treatments.